| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges CC Lai, TP Shih, WC Ko, HJ Tang, PR Hsueh International journal of antimicrobial agents 55 (3), 105924, 2020 | 7648 | 2020 |
| Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths CC Lai, YH Liu, CY Wang, YH Wang, SC Hsueh, MY Yen, WC Ko, ... Journal of Microbiology, Immunology and Infection 53 (3), 404-412, 2020 | 1203 | 2020 |
| Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical … DL Paterson, WC Ko, A Von Gottberg, JM Casellas, L Mulazimoglu, ... Journal of clinical microbiology 39 (6), 2206-2212, 2001 | 866 | 2001 |
| International Prospective Study of Klebsiella pneumoniae Bacteremia: Implications of Extended-Spectrum β-Lactamase Production in Nosocomial Infections DL Paterson, WC Ko, AV Gottberg, S Mohapatra, JM Casellas, ... Annals of internal medicine 140 (1), 26-32, 2004 | 846 | 2004 |
| Antibiotic Therapy for Klebsiella pneumoniae Bacteremia: Implications of Production of Extended-Spectrum β-Lactamases DL Paterson, WC Ko, A Von Gottberg, S Mohapatra, JM Casellas, ... Clinical infectious diseases 39 (1), 31-37, 2004 | 802 | 2004 |
| Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns WC Ko, DL Paterson, AJ Sagnimeni, DS Hansen, A Von Gottberg, ... Emerging infectious diseases 8 (2), 160, 2002 | 720 | 2002 |
| Epidemiology of Ciprofloxacin Resistance and Its Relationship to Extended-Spectrum β-Lactamase Production in Klebsiella pneumoniae Isolates Causing … DL Paterson, L Mulazimoglu, JM Casellas, WC Ko, H Goossens, ... Clinical Infectious Diseases 30 (3), 473-478, 2000 | 604 | 2000 |
| An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome VL Yu, CCC Chiou, C Feldman, A Ortqvist, J Rello, AJ Morris, LM Baddour, ... Clinical Infectious Diseases 37 (2), 230-237, 2003 | 565 | 2003 |
| Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia LM Baddour, VL Yu, KP Klugman, C Feldman, A Ortqvist, J Rello, ... American journal of respiratory and critical care medicine 170 (4), 440-444, 2004 | 542 | 2004 |
| Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and … CC Lai, CY Wang, YH Wang, SC Hsueh, WC Ko, PR Hsueh International journal of antimicrobial agents 55 (4), 105946, 2020 | 491 | 2020 |
| Nanoparticles in the treatment of infections caused by multidrug-resistant organisms NY Lee, WC Ko, PR Hsueh Frontiers in pharmacology 10, 452171, 2019 | 455 | 2019 |
| Association between rmpA and magA Genes and Clinical Syndromes Caused by Klebsiella pneumoniae in Taiwan WL Yu, WC Ko, KC Cheng, HC Lee, DS Ke, CC Lee, CP Fung, ... Clinical infectious diseases 42 (10), 1351-1358, 2006 | 453 | 2006 |
| Metallo-β-Lactamases in ClinicalPseudomonas Isolates in Taiwan and Identification of VIM-3, a Novel Variant of the VIM-2 Enzyme JJ Yan, PR Hsueh, WC Ko, KT Luh, SH Tsai, HM Wu, JJ Wu Antimicrobial agents and chemotherapy 45 (8), 2224-2228, 2001 | 422 | 2001 |
| Extra-respiratory manifestations of COVID-19 CC Lai, WC Ko, PI Lee, SS Jean, PR Hsueh International journal of antimicrobial agents 56 (2), 106024, 2020 | 408 | 2020 |
| Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 … P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ... The Lancet 393 (10167), 143-155, 2019 | 405 | 2019 |
| Arguments in favour of remdesivir for treating SARS-CoV-2 infections WC Ko, JM Rolain, NY Lee, PL Chen, CT Huang, PI Lee, PR Hsueh International journal of antimicrobial agents 55 (4), 105933, 2020 | 395 | 2020 |
| Virulence characteristics of Klebsiella and clinical manifestations of K. pneumoniae bloodstream infections LY Victor, DS Hansen, WC Ko, A Sagnimeni, KP Klugman, ... Emerging infectious diseases 13 (7), 986, 2007 | 383 | 2007 |
| Comparison of prevalence of virulence factors for Klebsiella pneumoniae liver abscesses between isolates with capsular K1/K2 and non-K1/K2 serotypes WL Yu, WC Ko, KC Cheng, CC Lee, CC Lai, YC Chuang Diagnostic microbiology and infectious disease 62 (1), 1-6, 2008 | 355 | 2008 |
| Increased antimicrobial resistance during the COVID-19 pandemic CC Lai, SY Chen, WC Ko, PR Hsueh International journal of antimicrobial agents 57 (4), 106324, 2021 | 354 | 2021 |
| Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia NY Lee, HC Lee, NY Ko, CM Chang, HI Shih, CJ Wu, WC Ko Infection Control & Hospital Epidemiology 28 (6), 713-719, 2007 | 285 | 2007 |
